These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17699164)

  • 21. Effect of angiotensin receptor blockers on myocardial infarction: what are we to believe?
    Ker JA; Rheeder P
    Cardiovasc J S Afr; 2005; 16(2):81-2. PubMed ID: 15915272
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
    Baer JT; Sauer WH; Berlin JA; Kimmel SE
    Am J Cardiol; 2004 Aug; 94(4):479-81. PubMed ID: 15325933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA; Giles TD
    Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent updates for high risk cardiovascular patient and "very" recent updates for the "very" elderly].
    Waeber B; Battegay E
    Praxis (Bern 1994); 2008 May; 97(10):526-7. PubMed ID: 18595367
    [No Abstract]   [Full Text] [Related]  

  • 29. [Interview with Prof. Peter Dominiak, Lübeck. "Risk of diabetes with antihypertensive drugs is clinically relevant" (interview by Dr. Angelika Bischoff)].
    Dominiak P
    MMW Fortschr Med; 2004 Dec; 146(51-52):51. PubMed ID: 15675248
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy of calcium channel blocker in hypertensive patients with chronic kidney disease].
    Morihira M; Kikuchi K; Nakagawa N; Fujino T; Hasebe N
    Nihon Jinzo Gakkai Shi; 2009; 51(4):451-5. PubMed ID: 19601552
    [No Abstract]   [Full Text] [Related]  

  • 31. Angiotensin receptor blockers and myocardial infarction.
    Verma S; Strauss M
    BMJ; 2004 Nov; 329(7477):1248-9. PubMed ID: 15564232
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modern clinical management of arterial hypertension: fixed or free combination therapies? Foreword.
    Trimarco B
    High Blood Press Cardiovasc Prev; 2011 Sep; 18 Suppl 1():1-2. PubMed ID: 21895048
    [No Abstract]   [Full Text] [Related]  

  • 35. On target to dual block RAS?
    Papadopoulos DP; Papademetriou V; Makris TK
    Angiology; 2009 Dec-2010 Jan; 60(6):739-49. PubMed ID: 19144653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Utilizing progress in modern antihypertensive therapy. Treating hypertension effectively from the beginning].
    MMW Fortschr Med; 2005 May; 147(19):48. PubMed ID: 15940938
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.
    Yousef ZR; Leyva F; Gibbs C
    BMJ; 2005 May; 330(7502):1270; author reply 1270-1. PubMed ID: 15920135
    [No Abstract]   [Full Text] [Related]  

  • 38. Blood pressure reduction is not the only determinant of outcome.
    Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR
    Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Arterial hypertension and chronic kidney disease].
    Mitchell A;
    MMW Fortschr Med; 2013 Oct; 155(17):55-7. PubMed ID: 24340391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.